Join your peers from December 10th to 13th, 2024, in Texas, USA, for this impactful symposium. Mark your calendars and be part of cutting-edge discussions on breast cancer research, prevention, diagnosis, and therapy
San Antonio Breast Cancer Symposium (SABCS) 2024
-
Event type:Symposium
-
Date10 Dec 2024 - 13 Dec 2024
-
Location
2024 San Antonio Breast Cancer Symposium (SABCS)
The 2024 San Antonio Breast Cancer Symposium (SABCS) is a premier event that brings together experts, researchers, and healthcare professionals from around the world. With a focus on cutting-edge information related to experimental biology, etiology, prevention, diagnosis, and therapy of breast cancer and premalignant breast disease, SABCS aims to advance our understanding and improve patient outcomes.
Key Highlights:
- Scientific Program: Attendees can expect formal lectures by experts in clinical, translational, and basic research. Additionally, there will be selected slide and poster presentations, forums, and case discussions.
- Audience: SABCS is directed primarily towards academic and private physicians, researchers, and patient advocates involved in breast cancer care across medical, surgical, gynecologic, and radiation oncology fields.
- Global Reach: Anticipating over 10,000 attendees from more than 102 countries, SABCS provides a unique opportunity for international collaboration and knowledge exchange.
Choose Your Participation: Participants can join in person at the Henry B. Gonzalez Convention Center in San Antonio, Texas, or virtually. Mark your calendars for December 10th - 13th, 2024, and be part of this impactful symposium.
Future breast cancer care: ESMO Breast Cancer 2024
Read about the latest updates in breast cancer research presented at ESMO Breast Cancer 2024, from the experts who attended.
More content available within our dedicated Learning Zones and Speciality Hubs
Breast Cancer
Containing relevant Learning Zones, guidelines, trials and news.
Oncology
Click here for our oncology learning resources
CDK4/6 inhibitors in breast cancer
Are you familiar with the clinical trial evidence that could help you to select the best cyclin dependent kinase 4/6 (CDK4/6) inhibitor for your metastatic breast cancer patient?